ZD6126

ZD6126 is a vasculature-disrupting agent that was developed by AstraZeneca for the treatment of cancer. It is a tubulin-binding agent that destabilizes tumor vasculature, leading to extensive tumor cell death.

Mechanism of Action

ZD6126 works by binding to the colchicine binding site of beta-tubulin, which leads to the destabilization of microtubules. This destabilization results in the disruption of the newly formed blood vessels within tumors, causing extensive tumor cell death.

Clinical Trials

ZD6126 has undergone Phase I and II clinical trials for the treatment of various types of cancer. However, the development of the drug was discontinued due to adverse side effects.

Side Effects

The most common side effects of ZD6126 include nausea, vomiting, and fatigue. Serious side effects can include neutropenia, thrombocytopenia, and anemia.

See Also

• Vascular disrupting agent
• Tubulin
• Microtubule
• AstraZeneca

References

ZD6126 Resources
Need Help Finding a Doctor? Need help finding a doctor or specialist anywhere in the world? Explore our world directory. WikiMD's DocFinder can assist you in locating millions of physicians.	Medical Knowledge Access the latest research - Most recent articles Ongoing trials.

Translate to: East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski